Yoshiyuki Yokomaku

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.

Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.

Journal: The lancet. HIV

Published: March 17, 2026

Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.

Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: October 06, 2025

Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.

Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: September 30, 2025

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

Journal: Lancet (London, England)

Published: August 04, 2025

Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies.

Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies.

Journal: Infectious diseases and therapy

Published: July 22, 2025

Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial.

Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: March 26, 2025

The unique structure of the highly conserved PPLP region in HIV-1 Vif is critical for the formation of APOBEC3 recognition interfaces.

The unique structure of the highly conserved PPLP region in HIV-1 Vif is critical for the formation of APOBEC3 recognition interfaces.

Journal: mBio

Published: January 21, 2025

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.

Journal: PloS one

Published: July 08, 2024

Antiretroviral therapies and status of people living with HIV in Japan: An update from hospital survey and national database.

Antiretroviral therapies and status of people living with HIV in Japan: An update from hospital survey and national database.

Journal: PloS one

Published: July 05, 2024

Investigating the Moderating Effect of HIV Status Disclosure on the Link Between Discrimination Experience and Psychological Distress Among People Living with HIV in Japan Infected Through Sexual Contact.

Investigating the Moderating Effect of HIV Status Disclosure on the Link Between Discrimination Experience and Psychological Distress Among People Living with HIV in Japan Infected Through Sexual Contact.

Journal: International journal of behavioral medicine

Published: June 10, 2024

Non-acquired immunodeficiency syndrome defining malignancies in people living with haemophilia and human immunodeficiency virus after direct-acting antiviral era.

Non-acquired immunodeficiency syndrome defining malignancies in people living with haemophilia and human immunodeficiency virus after direct-acting antiviral era.

Journal: Global health & medicine

Published: June 08, 2024

Population-based nanopore sequencing of the HIV-1 pangenome to identify drug resistance mutations.

Population-based nanopore sequencing of the HIV-1 pangenome to identify drug resistance mutations.

Journal: Scientific reports

Published: April 12, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026